GCL TECH (03800) completed the placement of 1.56 billion shares, raising approximately 15.3 billion Hong Kong dollars.
Xinjiang Silk Road Technology Co., Ltd. (03800) announced that it had completed the private placement of 1.56 billion shares of additional shares on January 3, 2025, raising net funds...
GCL TECH (03800) announced that it completed the placement of 1.56 billion shares of rights shares on January 3, 2025, raising approximately HK$1.53 billion. About 60% (approximately HK$920 million) will be used for the group's capital expenditure to develop and expand the group's CECEP Solar Energy related business, with the remaining 40% (approximately HK$610 million) reserved for general operating purposes to facilitate the group's operational activities.
Related Articles

Pre-market report on A shares | Concerns about high valuations trigger selling in US stocks! Cryptocurrencies and commodities fall collectively

STANCHART (02888) plans to issue $1 billion fixed rate reset perpetual callable convertible securities.

HUTCHMED (00013) announces the completion of patient recruitment for the SAFFRON global Phase III study of the combination therapy of sulfasalazine and terizsa for specific lung cancer patients with MET overexpression and/or amplification after treatment with terizsa.
Pre-market report on A shares | Concerns about high valuations trigger selling in US stocks! Cryptocurrencies and commodities fall collectively

STANCHART (02888) plans to issue $1 billion fixed rate reset perpetual callable convertible securities.

HUTCHMED (00013) announces the completion of patient recruitment for the SAFFRON global Phase III study of the combination therapy of sulfasalazine and terizsa for specific lung cancer patients with MET overexpression and/or amplification after treatment with terizsa.

RECOMMEND

World’s largest oil company Aramco posts higher Q3 net profit after lifting output
04/11/2025

HSBC, General Atlantic CEOs flag AI capex-revenue mismatch, ‘irrational exuberance’
04/11/2025

Pfizer Files Second Lawsuit Against Novo Nordisk and Metsera Amid Intensifying Bidding Battle Over Obesity Biotech
04/11/2025


